Search & Analyze

Anthem Biosciences Ltd.

HealthcarePharmaceuticals & Drugs

www.anthembio.com BSE: 544449NSE: ANTHEM

₹914.00BSE2.64%

16 Sep, 4:01 PM

₹914.00

₹51.20K Cr

88.90

16.36

21.98%

₹952.35

₹902.85

₹977.00

₹579.45

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.77	4,44,716.74	0.86	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.50	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.11	1,83,453.32	0.79	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.42	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.59	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	94.19	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.67	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Anthem Biosciences Ltd. ANTHEM	914.00	88.90	51,202.16	0.22	119.94	-11.67%	418.22	-22.58%	29.62

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	338.59	524.96	497.81	483.20	540.21	550.03	423.15	610.94	418.22
Expenses	217.69	329.72	338.30	288.00	348.72	332.12	265.95	343.73	267.65
	120.90	195.23	159.51	195.19	191.49	217.90	157.20	267.22	150.57
	35.71%	37.19%	32.04%	40.40%	35.45%	39.62%	37.15%	43.74%	36.00%
	19.46	27.85	24.37	14.06	22.81	48.23	8.16	52.19	24.89
Interest	3.70	3.55	2.55	0.52	1.61	3.03	0.35	1.90	0.89
	18.68	19.99	20.28	30.42	26.45	33.50	34.53	39.59	29.99
	117.98	199.53	161.05	178.31	186.25	229.60	130.47	277.92	144.58
	30.17%	18.85%	22.80%	53.66%	27.09%	24.47%	28.86%	31.72%	17.04%
	82.38	161.93	124.33	82.62	135.79	173.43	92.82	189.76	119.94
	1.47	2.90	2.22	1.48	2.42	3.09	1.65	3.38	2.13

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	1,231.26	1,056.92	1,419.37	1,850.63	2,183.06
	1,231.26	1,056.92	1,419.37	1,844.55	2,124.33
EXPENDITURE :
Increase/Decrease in Stock	-1.37	-9.01	-41.23	-86.71	98.69
Raw Material Consumed	410.30	348.29	640.79	830.62	713.59
Power & Fuel Cost	36.33	39.01	32.13	48.18	60.36
Employee Cost	137.51	153.24	182.93	260.09	281.24
Other Manufacturing Expenses	50.20	51.87	57.38	61.12	61.78
General and Administration Expenses	19.59	25.06	24.10	38.21	41.67
Selling and Distribution Expenses	9.74	9.84	7.93	13.09	9.99
Miscellaneous Expenses	1.85	15.75	10.26	8.92	23.04
	664.15	634.05	914.27	1,173.52	1,290.36
Operating Profit (Excl OI)	567.10	422.87	505.10	671.03	833.97
	48.98	85.04	63.70	85.73	155.78
	616.09	507.91	568.80	756.77	989.76
Interest	12.19	8.72	9.66	10.53	7.06
PBDT	603.90	499.19	559.14	746.24	982.70
	57.76	63.70	81.82	89.37	134.07
Profit Before Taxation & Exceptional Items	546.14	435.50	477.32	656.87	848.63
Exceptional Income / Expenses		61.80			-24.39
	546.14	497.30	477.32	656.87	824.24
Provision for Tax	140.60	112.11	110.01	205.61	232.45
	405.54	385.19	367.31	451.26	591.79
Extra items				0.00	0.00
Consolidated Net Profit	405.54	385.19	367.31	451.26	591.79
Profit Balance B/F	607.92	974.24	1,220.12	1,516.57	1,922.71
Appropriations	1,013.46	1,359.42	1,587.43	1,967.83	2,514.50
Equity Dividend %					100.00%
	462.10	6.75	6.57	8.07	10.54
Adjusted EPS	7.11	6.75	6.57	8.07	10.54

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	8.78	114.10	111.82	111.82	112.34
Share Warrants & Outstandings				34.35	33.33
Total Reserves	1,346.22	1,626.57	1,812.84	2,263.70	2,896.84
Reserve excluding Revaluation Reserve	1,346.22	1,626.57	1,812.84	2,263.70	2,896.84
Revaluation reserve	0.00	0.00	0.00	0.00
	1,355.00	1,740.67	1,924.66	2,409.87	3,042.52
Secured Loans	5.90	96.19	111.66	47.03	27.73
Deferred Tax Assets / Liabilities	-15.94	-24.91	-41.40	-17.95	-27.32
Other Long Term Liabilities	26.71	8.34	16.64	16.94	16.96
Long Term Provisions	5.08	5.39	6.53	7.52	16.37
Total Non-Current Liabilities	21.74	85.01	93.44	53.54	33.74
Trade Payables	64.84	71.94	100.74	110.09	75.22
Other Current Liabilities	109.38	53.62	107.26	146.28	187.87
Short Term Borrowings	29.59	28.88	120.87	42.95	4.36
Short Term Provisions	145.37	124.44	129.76	185.92	262.27
Total Current Liabilities	349.19	278.87	458.63	485.23	529.71
Total Liabilities	1,725.93	2,104.55	2,476.72	2,948.64	3,605.97
Gross Block	703.16	883.91	996.30	1,299.72	1,506.73
Less: Accumulated Depreciation	374.15	435.02	513.78	594.61	723.50
Net Block	329.01	448.89	482.52	705.10	783.23
Capital Work in Progress	153.83	164.08	344.69	296.88	264.35
Non Current Investments	3.70	6.16	12.55	120.78	341.87
Long Term Investment	3.70	6.16	12.55	120.78	341.87
Long Term Loans & Advances	22.30	46.67	34.60	29.11	50.39
Other Non Current Assets	0.79	0.59	0.81	149.59	158.99
Total Non-Current Assets	509.62	666.38	875.17	1,301.47	1,598.82
Currents Investments	269.13	492.87	459.07	312.29	665.59
Inventories	58.23	129.42	211.35	340.43	124.52
Sundry Debtors	326.19	274.07	490.45	450.40	590.59
Cash and Bank	348.90	342.85	184.36	172.28	274.88
Other Current Assets	9.83	3.16	3.36	9.73	7.49
Short Term Loans and Advances	204.02	195.81	252.97	362.04	344.09
Total Current Assets	1,216.31	1,438.17	1,601.55	1,647.17	2,007.15
Net Current Assets (Including Current Investments)	867.12	1,159.30	1,142.93	1,161.94	1,477.43
Total Assets	1,725.93	2,104.55	2,476.72	2,948.64	3,605.97
Contingent Liabilities	5.55	226.00	250.14	54.44	90.20
Total Debt	35.49	125.07	232.53	108.96	51.07
	1,543.98	30.51	34.43	42.49	53.57
Adjusted Book Value	23.75	30.51	34.43	42.49	53.57

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	546.14	497.30	477.32	656.87	824.24
Adjustment	48.67	27.32	44.83	73.38	84.83
Changes In working Capital	-138.90	-103.63	-262.00	-300.69	139.42
Cash Flow after changes in Working Capital	455.91	420.99	260.15	429.55	1,048.49
Cash Flow from Operating Activities	332.91	305.99	140.15	270.55	844.49
Cash Flow from Investing Activities	-205.45	-376.02	-221.46	-146.56	-701.62
Cash Flow from Financing Activitie	180.68	63.97	-77.18	-135.65	-40.00
Net Cash Inflow / Outflow	308.14	-6.06	-158.49	-11.66	102.87
Opening Cash & Cash Equivalents	40.77	348.90	342.85	184.36	172.28
Effect of Foreign Exchange Fluctuations				-0.41	-0.27
Closing Cash & Cash Equivalent	348.90	342.85	184.36	172.28	274.88

Ratios

Valuation

88.90

16.36

53.62

25.57

10.22

55.53

Profitability

21.98

29.62

18.06

38.20

27.11

Leverage & Liquidity

0.02

3.79

117.83

Returns

0.22

0.67

Shareholding Pattern

Numbers in percentages

Particulars	Jul '25	Sep '25	Dec '25	Mar '26	Jun '26
	74.69	74.69	74.69	74.68	71.42
	5.10	8.89	8.96	12.83	16.06
	20.22	16.42	16.35	12.49	12.53
	25.31	25.31	25.31	25.32	28.58
No. of Shareholders	8,25,844	2,17,681	1,99,492	1,80,220	1,73,273

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-07-14	Board Meeting	Quarterly Results
2026-05-26	AGM
2026-05-19	Ex Dividend	Rs.2.0000 per share(100%)Final Dividend	2026-06-25	2026-06-26

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Anthem Biosciences Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

9 members across the board and senior leadership

Ajay Bhardwaj

Chairman & Managing Director, Chief Executive Officer

₹6.46 Cr

Mar '26

Ganesh Sambasivam

Whole Time Director

₹6.52 Cr

Mar '26

K Ravindra Chandrappa

Whole Time Director

₹6.55 Cr

Mar '26

Satish Chander Subbanna

Nominee Director

—

Subramanian Madhavan

Non Executive Independent Director

₹36.80 L

Mar '26

Ravikant Uppal

Non Executive Independent Director

₹30.20 L

Mar '26

Ramesh Ramadurai

Non Executive Independent Director

₹35.80 L

Mar '26

Shubha Kulkarni

Non Executive Independent Women Director

₹24.00 L

Mar '26

Divya Prasad

Company Secretary & Compliance Officer

—

ANTHEM Latest News

News

3 of 3 articles

EQUITY27 Jul 2026 · 12:56

Anthem Biosciences informs about transcript of conference call

EQUITY20 May 2026 · 16:59

Anthem Biosciences informs about newspaper publication

EQUITY19 May 2026 · 19:06

Anthem Biosciences reports Profit after tax of Rs 2116.64 Mln, in the March 2026 quarter

ANTHEM

₹914.00

-2.64%